Risdiplam Patent Expiration

Risdiplam is Used for treating spinal muscular atrophy. It was first introduced by Genentech Inc in its drug Evrysdi on Aug 7, 2020.


Risdiplam Patents

Given below is the list of patents protecting Risdiplam, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Evrysdi US11534444 Treatment of SMA Oct 04, 2038 Genentech Inc
Evrysdi US11938136 Compositions for treating spinal muscular atrophy Nov 08, 2036 Genentech Inc
Evrysdi US11827646 Compounds for treating spinal muscular atrophy Jan 25, 2036 Genentech Inc
Evrysdi US9969754 Compounds for treating spinal muscular atrophy May 11, 2035 Genentech Inc
Evrysdi US9586955 Compounds for treating spinal muscular atrophy Feb 08, 2033 Genentech Inc



Risdiplam's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Risdiplam News

Health organizations express worries about exclusive rights for medications treating rare diseases - Report from The Economic Times

05 Nov, 2024

See More